E-ISSN 2636-834X

Review Article 

Pharmacotherapy of Personality Disorders

Demet Güleç Öyekçin, Deniz Kutluay.

The prevalence of Personality disorders (PD) is high among psychiatric patients who have consulted and have been diagnosed as psychiatric illness. The prevalence of personality disorders (PD) among general population varies as %10-13 and the prevalence of PD among psychiatric outpatients is %30-50 and %15 among inpatients. The most common PDs are regarded as Borderline Personality Disorder (BPD), Antisocial Personality Disorder (APD), Schizotypal Personality Disorder (SPD) and Avoidant Personality Disorder (AvPD). These four disorders may cause impairments in social functioning and professional breakdown, suicidal behavior, substance abuse and cognitive impairment. Patients who have the diagnosis of PD generally apply to primary care and mental health services and the data, which is related to these patients’ use of the medical treatment service opportunity, the increase of medical health care cost and social obligations, has been gradually growing.
The aim of this article is to review double-blind, controlled studies of psychotropic drugs to evaluate the evidence base supporting their use in treatment of personality disorder.
Personality Disorder appearing with different facts and mental disorders does not have a unique treatment and a suitable treatment for patients, clinic symptoms accompanying mental disorders needs to be specially planned. There are numerous psychotropic treatments in Personality Disorder. However, there have been some doubts about the efficiency of them. The aim of this study is to observe the efficiency of psychotropic pharmacologic treatment on PD.
Literature cited in pubmed published between 1980 and 2011 was searched using the following terms: personality disorder, borderline, antisocial, schizotypal, narsistic, schizoid, obsessive-compulsive, avoidant personality disorder, medication and pharmacotherapy. While reports of double-blind, randomized, controlled trials were included, some open-lable trails have taken account.
The observations are significantly related in BPD treatment. Widely-used multi drug medication in BPD diagnosed patients is regarded as not efficient at all. Mood stabilizator drugs seem to take place of antidepresssant treatment whereas use of antidepresant treatment reduces the affective symptoms, such as severe anger and disphoria which facilitates psychotherapy treatment. Mood stabilizators, especially divalproic asit, is suggested to efficiant on anger dimention of BPD. Results suggest that primer treatment of APD is cognitive behavioral therapy and there is insufficient trial evidence to justify using any pharmacoterapic interventions. Different treatment choices can be developed understanding the etiology of disfunctional emotional empathy in APD, with in progressive neurobiological treatment. It is regarded that antipsychotic treatment is efficent in schizotypal personality disorder that is assesed in schiozophrenia spectrum disord

Key words: Personality disorders, pharmacotherapy, borderline personality disorder

How to cite this articleHow to cite this article
Citation Tools
Related Records
 Articles by Demet Güleç Öyekçin
Articles by Deniz Kutluay
on Google
on Google Scholar

1. Spitzer RL, Gibbon M, W, Skodol AE, Williams JBW, Michael B, First MB. Case Book. A Learning Companian to the Diagnostic and Statistical Manual of Mental Disorders Fourth Edition Text Version. American Psychiatric Publishing Inc.2002
2. American Psychiatric Association. Diagnostic and statistical manual of mental disorders 4th ed. Washington, DC 1994.
3. Widiger TA, Weissman MM. Epidemiology of borderline personality disorder. Hosp Community Psychiatry 1991; 42(10): 1015-1021. [Pubmed]   
4. Rinne T, Van den Brink W, Wouters L, van Dyck R. SSRI treatment of borderline personality disorder: a randomized, placebo-controlled clinical trial for female patients with borderline personality disorder. Am J Psychiatry 2002;159:2048–2054. [DOI via Crossref]    [Pubmed]   
5. Gross R, Olfson M, Gameroff M, Shea S, Feder A, Fuentes M, Lantigua R, Weissman MM. Borderline personality disorder in primary care. Arch Intern Med 2002; 14: 162(1):53-60.
6. Vedat Þ. DSM-5 Taslak taný ölçütlerine genel bir bakýþ: "Batý cephesinde yeni bir þey yok"mu? Klinik Psikiyatri Dergisi 2010; 13: 196-208.
7. American Psychiatric Association DSM-V development (2010)http://www.dsm5.org Proposed Revisions/Pages/Personality and PersonalityDisorders.aspx.
8. Cloninger C.R, Svrakic DM, Przybeck TR. A psychological model of temperament and character. Arch Gen Psychiatry 1993;50: 975–990. [DOI via Crossref]   
9. Hori A. Pharmacotherapy for personality disorders. Psychiatry Clin Neurosci 1998; 52: 13-19. [DOI via Crossref]    [Pubmed]   
10. Lenzenweger MF, Lane MC, Loranger AW, Kessler RC. DSM-IV personality disorders in the National Comorbidity Survey Replication. Biol Psychiatry 2007; 62: 553–564. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
11. Al-Alem L, Omar HA. Borderline personality disorder: an overview of history, diagnosis and treatment in adolescents. Int J Adolesc Med Health 2008 Oct-Dec;20(4):395-404. [Pubmed]   
12. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders.(DSM-IV) (1994) Washington D.C:American Psychiatric Association. Türkçe çevirisi :E Köroðlu ve ark.Ankara Hekimler Yayýn birliði.
13. McGlashan TH, Grilo CM, Skodol AE, Gunderson JG, Shea MT, Morey LC, Zanarini MC, Stout RL. The Collaborative Longitudinal Personality Disorders Study: baseline Axis I/II and II/II diagnostic cooccurrence. Acta Psychiatr Scand 2000;102(4):256–264. [DOI via Crossref]    [Pubmed]   
14. Sansone RA, Sansone LA. Gender Patterns in Borderline Personality Disorder Innov Clin Neurosci 2011;8(5):16-20.
15. Soloff PH, Lynch KG, Kelly TM. Childhood abuse as a risk factor for suicidal behavior in borderline personality disorder. J Pers Disord 2002;16(3):201–214. [DOI via Crossref]    [Pubmed]   
16. Black DW, Blum N, Pfohl B, Hale N. Suicidal behavior in borderline personality disorder: prevalence, risk factors, prediction and prevention. J Pers Disord 2004;18(3):226-239. [DOI via Crossref]    [Pubmed]   
17. Akiskal HS. Demystifying borderline personality: critique of the concept and unorthodox reflections on its natural kinship with the bipolar spectrum. Acta Psychiatr Scand 2004;110(6):401–407. [DOI via Crossref]    [Pubmed]   
18. Paris J, Gunderson J, Weinberg I. The interface between borderline personality disorder and bipolar spectrum disorders. Compr Psychiatry 2007;48(2):145–154. [DOI via Crossref]    [Pubmed]   
19. American Psychiatric Association. Practic guideline for the treatment of patients with borderline personality disorder: Treatment recommandations for patients with borderline personality disorder: executive summary of recomandations, Washington DC 2001, p:2
20. Abraham PF, Calabrese JR. Research report Evidenced-based pharmacologic treatment of borderline personality disorder: A shift from SSRIs to anticonvulsants and atypical antipsychotics? J Affect Disord 2008; 111: 21–30. [DOI via Crossref]    [Pubmed]   
21. Zanarini MC, Frankenburg FR, Reich DB, Silk KR, Hudson JI, McSweeney LB. The subsyndromal phenomenology of borderline personality disorder: a 10-year follow-up study. Am J Psychiatry 2007;164(6):929–935. [DOI via Crossref]    [Pubmed]   
22. Feurino L, Silk KR.State of the Art in the Pharmacologic Treatment of Borderline Personality Disorder. Curr Psychiatry Rep 2011;13(1):69-75. [DOI via Crossref]    [Pubmed]   
23. Mercer D, Douglass AB, Links PS. Meta-analyses of mood stabilizers, antidepressants and antipsychotics in the treatment of borderline personality disorder: effectiveness for depression and anger symptoms. J Pers Disord 2009;23(2):156-174. [DOI via Crossref]    [Pubmed]   
24. Pittenger C, Duman RS. Stress, depression, and neuroplasticity: A convergence of mechanisms. Neuropsychopharmacology 2008; 33: 88–109. [DOI via Crossref]    [Pubmed]   
25. Glenn AL, Raine A. The neurobiology of psychopathy. Psychiatr Clin North Am 2008; 31: 463-475. [DOI via Crossref]    [Pubmed]   
26. Salzman C, Wolfson AN, Schatzberg A, Looper J, Henke R, Albanese M, Schwartz J, Miyawaki. Effect of fluoxetine on anger in symptomatic volunteers with borderline personality disorder. J Clin Psychopharmacol 1995;15(1):23-29. [DOI via Crossref]    [Pubmed]   
27. Coccaro EF, Kavoussi RJ. Fluoxetine and impulsive aggressive behavior in personality-disordered subjeets. Arch Gen Psychiatry 1997; 54: 1081-1088. [DOI via Crossref]   
28. Simpson EB, Yen S, Costello E, Rosen K, Begin A, Pistorello J, Pearlstein T. Combined dialectical behavior therapy and fluoxetine in the treatment of borderline personality disorder. J Clin Psychiatry 2004; 65: 379-385. [DOI via Crossref]    [Pubmed]   
29. Kool S, Dekker J, Duijsens IJ, de Jonghe F, Puite B. Effieacy of combined therapy and pharmacotherapy for depressed patients with or without personality disorders. Harv Rev Psychiatry 2003; 1:133-141. [DOI via Crossref]   
30. Norden MJ. Fluoxetine in borderline personality disorder. Prog Neuorpsychopharmacol Biol Psychiatr 1989, 13: 885–893. [DOI via Crossref]   
31. Cornelius JR, Soloff PH, Perel JM, Ulrich RF. Fluoxetine trial in borderline personality disorder. Psychopharmacol Bull 1990; 26:151–154. [Pubmed]   
32. Markowitz PJ, Calabrese, Schulz SC, Meltzer HY. Fluoxetine in the treatment of borderline and schizotypal personality disorders. Am J Psychiatry 1991;148:1064–1067.
33. Zanarini MC, Frankenburg FR, Parachini EA. A preliminary, randomized trial of fluoxetine, olanzapine, and the olanzapine fluoxetine combination in women with borderline personality disorder. J Clin Psychiatry 2004;65(7):903-907. [DOI via Crossref]    [Pubmed]   
34. Bellino S, Paradiso E, Bozzatello P, Bogetto F. Efficacy and tolerability of duloxetine in borderline personality disorder a pilot study. J Psychopharmacol 2010; 24(3): 333-339. [DOI via Crossref]    [Pubmed]   
35. Frankenburg FR, Zanarini MC. Clozapine treatment in borderline patients: a preliminary study. Compr Psychiatry 1993; 34: 402–405. [DOI via Crossref]   
36. Benedetti F, Sforzini L, Colombo C, Maffei C, Smeraldi E. Low-dose clozapine in acute and continuation treatment of severe borderline personality disorder. J Clin Psychiatry 1998 Mar;59(3):103-107. [DOI via Crossref]    [Pubmed]   
37. Schulz SC, Camlin KL, Berry SA, Jesberger JA. Olanzapine safety and efficacy in patients with borderline personality disorder and comorbid dysthymia. Biol Psychiatry 1999;46: 1429–1435. [DOI via Crossref]   
38. Schulz SC, Zanarini MC, Bateman A, Bohus M, Detke HC, Trzaskoma Q, Tanaka Y, Lin D, Deberdt W, Corya S. Olanzapine for the treatment of borderline personality disorder: variable dose 12-week randomised double-blind placebo-controlled study. Br J Psychiatry 2008;193(6):485-492. [DOI via Crossref]    [Pubmed]   
39. Nickel MK, Muehlbacher M, Nickel C, Kettler C, Pedrosa Gil F, Bachler E, Buschmann W, Rother N, Fartacek R, Egger C, Anvar J, Rother WK, Loew TH, Kaplan P.Aripiprazole in the treatment of patients with borderline personality disorder: a double-blind, placebo-controlled study. Am J Psychiatry. 2006 May;163(5):833-838. [DOI via Crossref]    [Pubmed]   
40. Johnson DM, Shea MT, Yen S, Battle CL, Zlotnick C, Sanislow CA, Grilo CM, Skodol AE, Bender DS, McGlashan TH, Gunderson JG, Zanarini MC. Gender differences in borderline personality disorder: findings from the Collaborative Longitudinal Personality Disorders Study. Compr Psychiatry 2003;44: 284–292. [DOI via Crossref]   
41. Zanarini MC, Frankenburg FR, Dubo ED, Sickel AE, Trikha A, Levin A, Reynolds V. Axis I comorbidity of borderline personality disorder. Am J Psychiatry 1998;155:1733–1739. [Pubmed]   
42. Hollander, E, Allen A, Lopez RP, Bienstock C, Grossman R, Siever L, Margolin L, Stein D. A preliminary double blind placebo-controlled trial of divalproex sodium in borderline personality disorder. J Clin Psychiatry 2001; 62: 199–203. [DOI via Crossref]    [Pubmed]   
43. Frankenburg FR, Zanarini MC. Divalproex sodium treatment of women with borderline personality disorder and bipolar II disorder: a double-blind placebo-controlled pilot study. J Clin Psychiatry 2002;63(5):442-446. [DOI via Crossref]   
44. Hollander E, Tracy KA, Swann AC, Coccaro EF, McElroy SL, Wozniak P, Sommerville KW, Nemeroff CB. Divalproex in the treatment of impulsive aggression: efficacy in cluster B personality disorders. Neuropsychopharmacology 2003; 28: 1186–1197. [Pubmed]   
45. Hollander E. Swann AC. Coccaro EF. Jiang P. Smith TB. Impac of trait impulsivity and state agression on divalproex versus plasebo response in borderline personality disorder. Am J Psychiatry 2005; 162: 621-624. [DOI via Crossref]    [Pubmed]   
46. De la Fuente JM, Lotstra F. A trial of karbamazepine in borderline personality disorder. Eur Neuropsychopharmacol 1994;4: 479-486. [DOI via Crossref]   
47. Cowdry RW, Gardner DL. Pharmacotherapy of borderline personality disorder: alprazolam, carbamazepine, trifluoperazine and tranylcypromine. Arch Gen Psychiatry 1988; 45:111–119. [DOI via Crossref]   
48. Reich DB, Zanarini MC, Bieri KA. A preliminary study of lamotrigine in the treatment of affective instability in borderline personality disorder. Int Clin Psychopharmacol 2009; 24(5):270-275. [Pubmed]   
49. Saunders EFH, Silk K. Personality trait dimensions and the pharmacologic treatment of borderline personality disorder. J Clin Psychopharm 2009; 29: 461-467. [DOI via Crossref]    [Pubmed]   
50. Zanarini MC, Frankenburg FR. Omega-3 fatty acid treatment of women with borderline personality disorder: a double blind placebo controlled pilot study. Am J Psychiatry 2003;160:167-169. [DOI via Crossref]   
51. Philipsen A, Richter H, Schmahl C, Peters J, Rüsch N, Bohus M, Lieb K. Clonidine in acute aversive inner tension and self-injurious behavior in female patients with borderline personality disorder. J Clin Psychiatry 2004; 65(10):1414-1419. [DOI via Crossref]    [Pubmed]   
52. Ziegenhorn AA, Roepke S, Schommer NC, Merkl A, Danker-Hopfe H, Perschel FH, Heuser I, Anghelescu IG, Lammers CH. Clonidine improves hyperarousal in borderline personality disorder with or without comorbid posttraumatic stress disorder: a randomized, double-blind, placebo-controlled trial. Psychopharmacology 2009;29(2):170-173.
53. Rodrigo C, Rajapakse S, Jayananda G.The 'antisocial' person: an insight in to biology, classification and current evidence on treatment. Ann Gen Psychiatry 2010; 9: 31. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
54. Shirtcliff EA, Vitacco MJ, Graf AR, Gostisha AJ, Merz JL, Zahn-Waxler C. Neurobiology of Empathy and Callousness: Implications for the Development of Antisocial Behavior. Behav Sci Law 2009; 27(2): 137–171. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
55. Marsh AA, Finger EC, Mitchell DG, Reid ME, Sims C, Kosson DS, Towbin KE, Leibenluft E, Pine DS, Blair RJ. Reduced amygdala response to fearful expressions in children and adolescents with callous-unemotional traits and disruptive behavior disorders. Am J Psychiatry 2008;165:712-720. [DOI via Crossref]    [Pubmed]   
56. Rhee SH, Waldman ID. Genetic and environmental influences on antisocial behavior: a metaanalysis of twin and adoption studies. Psychol Bull 2002;128:490-529. [DOI via Crossref]   
57. National Institute for Health and Clinical Excellence: Antisocial Personality Disorder: treatment, management and prevention Volume 77. London, UK: National Collaborating Center for Mental Health; 2009.
58. Ripoll LH, Triebwasser J, Siever LJ. Evidence-based pharmacotherapy for personality disorders. Int J Neuropsychopharmacol 2011; 15: 1-32.
59. Barratt ES, Stanford MS, Felthous AR, Kent TA. The effects of phenytoin on impulsive and premeditated aggression: a controlled study. J Clin Psychopharmacol 1997 Oct;17(5):341-349. [DOI via Crossref]    [Pubmed]   
60. Hirose S. Effective treatment of aggression and impulsivity in antisocial personality disorder with risperidone. Psychiatry Clin Neurosci 2001; 55:161-162. [DOI via Crossref]    [Pubmed]   
61. Savitz J, Van der Merwe L, Newman TK, Stein DJ, Ramesar R. Catechol-o-methyltransferase genotype and childhood trauma may interact to impact schizotypal personality traits. Behav Genet 2010 May;40(3):415-423. [DOI via Crossref]    [Pubmed]   
62. Suzuki M, Zhou SY, Hagino H, Takahashi T, Kawasaki Y, Nohara S, Yamashita I, Matsui M, Seto H, Kurachi M. Volume reduction of the right anterior limb of the internal capsule in patients with schizotypal disorder. Psychiatry Res 2004 Apr 30;130(3):213-225. [DOI via Crossref]    [Pubmed]   
63. McClure MM, Barch DM, Romero MJ, Minzenberg MJ, Triebwasser J, Harvey PD, Siever LJ. The effects of guanfacine on context processing abnormalities in schizotypal personality disorder. Biol Psychiatry 2007 May 15;61(10):1157-1160. [DOI via Crossref]    [Pubmed]   
64. McClure MM, Harvey PD, Goodman M, Triebwasser J, New A, Koenigsberg HW, Sprung LJ, Flory JD, Siever LJ. Pergolide treatment of cognitive deficits associated with schizotypal personality disorder: continued evidence of the importance of the dopamine system in the schizophrenia spectrum. Neuropsychopharmacology 2010 May;35(6):1356-1362. [DOI via Crossref]    [Pubmed]    [PMC Free Fulltext]   
65. Koenigsberg HW, Reynolds D, Goodman M, New AS, Mitropoulou V, Trestman RL, Silverman J, Siever LJ. Risperidone in the treatment of schizotypal personality disorder. J Clin Psychiatry 2003;64(6):628-634. [DOI via Crossref]    [Pubmed]   
66. Tillfors M, Furmark T, Ekselius L, Fredrikson M. Social phobia and avoidant personality disorder: One spectrum disorder? Nord J Psychiatry 2004;58: 147–152. [DOI via Crossref]    [Pubmed]   
67. Alden LE, Laposa JM, Taylor CT, Ryder AG. Avoidant personality disorder: current status and future directions. J Pers Disord 2002 Feb;16(1):1-29. [DOI via Crossref]    [Pubmed]   
68. Stein MB, Pollack MH, Bystritsky A, Kelsey JE, Mangano RM. Efficacy of low and higher dose extended-release venlafaxine in generalized social anxiety disorder: a 6-month randomized controlled trial. Psychopharmacology (Berl) 2005 Jan;177(3):280-288. [DOI via Crossref]    [Pubmed]   
69. Allgulander C, Mangano R, Zhang J, Dahl AA, Lepola U, Sjödin I, Emilien G. Efficacy of Venlafaxine ER in patients with social anxiety disorder: a double-blind, placebo-controlled, parallel-group comparison with paroxetine. Hum Psychopharmacol 2004 Aug;19(6):387-396. [DOI via Crossref]    [Pubmed]   
70. Van Ameringen M, Oakman J, Mancini C, Pipe B, Chung H. Predictors of response in generalized social phobia: effect of age of onset. J Clin Psychopharmacol 2004 Feb;24(1):42-48. [DOI via Crossref]    [Pubmed]   
71. Davidson JR. Pharmacotherapy of social anxiety disorder: what does the evidence tell us? J Clin Psychiatry 2006; 67 Suppl 12: 20-26. [Pubmed]   
72. Pande AC, Davidson JR, Jefferson JW, Janney CA, Katzelnick DJ, Weisler RH, Greist JH, Sutherland SM. Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 1999;19: 341–348. [DOI via Crossref]    [Pubmed]   
73. Pande AC, Feltner DE, Jefferson JW, Davidson JR, Pollack M, Stein MB, Lydiard RB, Futterer R, Robinson P, Slomkowski M, DuBoff E, Phelps M, Janney CA, Werth JL. Efficacy of the novel anxiolytic pregabalin in social anxiety disorder. J Clin Psychopharmacol 2004; 24: 141–149. [DOI via Crossref]    [Pubmed]   
74. Montgomery SA, Nil R, Dürr-Pal N, Loft H, Boulenger JP. A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 2005 Oct;66(10):1270-1278. [DOI via Crossref]    [Pubmed]   
75. Liebowitz MR, Gelenberg AJ, Munjack D. Venlafaxine extended release vs placebo and paroxetine in social anxiety disorder. Arch Gen Psychiatry 2005 Feb;62(2):190-198. [DOI via Crossref]    [Pubmed]   
76. Kasper S, Stein DJ, Loft H, Nil R. Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 2005 Mar;186:222-226. [DOI via Crossref]    [Pubmed]   
77. Stein MB, Fyer AJ, Davidson JR, Pollack MH, Wiita B. Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 1999 May;156(5):756-760. [Pubmed]   
78. Katzelnick DJ, Kobak KA, Greist JH, Jefferson JW, Mantle JM, Serlin RC. Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 1995;152:1368-1371. [Pubmed]   
79. Van Ameringen MA, Lane RM, Walker JR, Bowen RC, Chokka PR, Goldner EM, Johnston DG, Lavallee YJ, Nandy S, Pecknold JC, Hadrava V, Swinson RP. Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 2001;158:275-281. [DOI via Crossref]    [Pubmed]   
80. Stein DJ, Versiani M, Hair T, Kumar R. Efficacy of paroxetine for relapse prevention in social anxiety disorder: a 24-week study. Arch Gen Psychiatry 2002;59(12):1111-1118. [DOI via Crossref]    [Pubmed]   
81. Leichsenring F, Leibing E, Kruse J, New AS, Leweke F. Borderline personality disorder. Lancet 2011;377(9759):74-84. [DOI via Crossref]   
82. Herpertz SC, Zanarini M, Schulz CS, Siever L, Lieb K, Möller HJ. WFSBP Task Force on Personality Disorders; World Federation of Societies of Biological Psychiatry (WFSBP). World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of personality disorders. World J Biol Psychiatry 2007;8(4):212-244. [DOI via Crossref]    [Pubmed]   
83. Kingsbury SJ, Yi D, Simpson GM. Psychopharmacology: Rational and Irrational Polypharmacy. Psychiatr Serv 2001; 52:1033-1036. [DOI via Crossref]    [Pubmed]   
84. Pascual JC, Martín-Blanco A, Soler J, Ferrer A, Tiana T, Alvarez E, Pérez V.A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol 2010;25(6):349-355. [DOI via Crossref]    [Pubmed]   

How to Cite this Article
Pubmed Style

Demet Güleç Öyekçin, Deniz Kutluay. [Pharmacotherapy of Personality Disorders]. PBS. 0; 0(0): -. Turkish.

Web Style

Demet Güleç Öyekçin, Deniz Kutluay. [Pharmacotherapy of Personality Disorders]. http://www.pbsciences.org/?mno=13382 [Access: September 28, 2021]. Turkish.

AMA (American Medical Association) Style

Demet Güleç Öyekçin, Deniz Kutluay. [Pharmacotherapy of Personality Disorders]. PBS. 0; 0(0): -. Turkish.

Vancouver/ICMJE Style

Demet Güleç Öyekçin, Deniz Kutluay. [Pharmacotherapy of Personality Disorders]. PBS. (0), [cited September 28, 2021]; 0(0): -. Turkish.

Harvard Style

Demet Güleç Öyekçin, Deniz Kutluay (0) [Pharmacotherapy of Personality Disorders]. PBS, 0 (0), -. Turkish.

Turabian Style

Demet Güleç Öyekçin, Deniz Kutluay. 0. [Pharmacotherapy of Personality Disorders]. Psychiatry and Behavioral Sciences, 0 (0), -. Turkish.

Chicago Style

Demet Güleç Öyekçin, Deniz Kutluay. "[Pharmacotherapy of Personality Disorders]." Psychiatry and Behavioral Sciences 0 (0), -. Turkish.

MLA (The Modern Language Association) Style

Demet Güleç Öyekçin, Deniz Kutluay. "[Pharmacotherapy of Personality Disorders]." Psychiatry and Behavioral Sciences 0.0 (0), -. Print.Turkish.

APA (American Psychological Association) Style

Demet Güleç Öyekçin, Deniz Kutluay (0) [Pharmacotherapy of Personality Disorders]. Psychiatry and Behavioral Sciences, 0 (0), -. Turkish.